"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

LONDON - GSK plc (LSE/NYSE:GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...

Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21 that is designed to regulate key metabolic pathways to decrease liver fat, ...

GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) GSK plc (LSE/NYSE: GSK) today announced ...

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) May 14, 2025 2:14 AM ET GSK plc (GSK) ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis significantly improved outcomes after 24 weeks.

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal. The transaction includes an ...